Nemko, a Norway-based notified body, has certified and granted CE mark to PCI Biotech's (PCIB) PCI 652nm laser.

PCIB said its PCI 652nm laser will be used in the Phase II study of Amphinex in head and neck cancer patients.

PCIB develops light directed drug delivery system based on the company’s patented photochemical internalisation (PCI) technology.

Based on the company’s PCI technology, the company follows a dual strategy to improve the effect both of existing drugs and gene therapy treatments.